NYSE · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Nanoviricides, Inc. NNVC
18 fiscal years on record · USD · FY2024 reported
SEC FILINGS ONLY
EPS · FY24
$-0.63
Dividend / sh · FY24
—
Payout · FY24
—
ROE · FY24
-99.7%
Net margin · FY24
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2024 · full 18-year series below
Revenue
Net income
Per share
USD -0.63
Diluted EPS, FY2024
EPS
The company pays no cash dividend.
Profitability
-99.7%
Return on equity, FY2024
ROE
Operating margin—
Net margin—
Return on assets-87.5%
Each USD of equity lost 100 cents this year.
Returned to shareholders
—
returned in FY2024 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.02B
Shares outstanding, FY2024
Change, 5 years+82.8%
Change, 10 years—
The share count grew 83% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 8.8M
total assets, end of FY2024
Total assetsUSD 8.8M
EquityUSD 7.5M
CashUSD 1.6M
Current ratio1.28×
Equity funds 85% of total assets.
History
18 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
Revenue $B
0.0
0.0
0.0
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
Income tax $B
·
·
·
·
·
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.63
−0.70
−0.74
−0.70
−0.81
−2.39
−2.35
−2.64
−0.17
−0.19
−0.09
−0.27
−0.19
−0.15
−0.16
−0.04
·
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−99.7
−63.0
−45.3
−30.6
−34.1
−83.1
−59.6
−45.1
−47.5
−39.1
−8.0
−86.7
−81.2
−51.7
−77.6
−105.4
−190.3
−617.1
Shares out B
0.02
0.01
0.01
0.01
0.01
0.01
0.00
0.07
0.06
0.06
0.06
0.05
0.05
0.04
0.14
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
46 of 46
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed